175 related articles for article (PubMed ID: 37872422)
41. [Endometriosis and fertility preservation: CNGOF-HAS Endometriosis Guidelines].
Decanter C; d'Argent EM; Boujenah J; Poncelet C; Chauffour C; Collinet P; Santulli P
Gynecol Obstet Fertil Senol; 2018 Mar; 46(3):368-372. PubMed ID: 29530556
[TBL] [Abstract][Full Text] [Related]
42. Medroxyprogesterone acetate: an alternative to GnRH-antagonist in oocyte vitrification for social fertility preservation and preimplantation genetic testing for aneuploidy.
Giles J; Cruz M; Cobo A; Vidal C; Requena A; Remohi J; Bosch E
Reprod Biomed Online; 2023 Aug; 47(2):103222. PubMed ID: 37290978
[TBL] [Abstract][Full Text] [Related]
43. [Fertility preservation in oncology].
Chaput L; Grémeau AS; Vorilhon S; Pons H; Chabrot C; Grèze V; Pouly JL; Brugnon F
Bull Cancer; 2018 Jan; 105(1):99-110. PubMed ID: 29221621
[TBL] [Abstract][Full Text] [Related]
44. Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles.
Herzberger EH; Knaneh S; Amir H; Reches A; Ben-Yosef D; Kalma Y; Azem F; Samara N
Reprod Sci; 2021 Dec; 28(12):3390-3396. PubMed ID: 34076872
[TBL] [Abstract][Full Text] [Related]
45. Navigating parent-child disagreement about fertility preservation in minors: scoping review and ethical considerations.
Bayefsky M; Vieira D; Caplan A; Quinn G
Hum Reprod Update; 2022 Aug; 28(5):747-762. PubMed ID: 35468184
[TBL] [Abstract][Full Text] [Related]
46. Fertility after breast cancer treatment.
Kasum M; Beketić-Orešković L; Peddi PF; Orešković S; Johnson RH
Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():13-8. PubMed ID: 24315568
[TBL] [Abstract][Full Text] [Related]
47. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?
Sonigo C; Simon C; Boubaya M; Benoit A; Sifer C; Sermondade N; Grynberg M
Hum Reprod; 2016 Jul; 31(7):1493-500. PubMed ID: 27165625
[TBL] [Abstract][Full Text] [Related]
48. How can fertility counseling be implemented for every newly diagnosed pediatric patient facing gonadotoxic treatment?-A single-center experience.
Barnbrock A; Salzmann-Manrique E; Sänger N; Fiegel H; Ochsendorf F; Klingebiel T; Bader P; Jarisch A
Ann Hematol; 2021 Nov; 100(11):2831-2841. PubMed ID: 34536088
[TBL] [Abstract][Full Text] [Related]
49. Vitrification of human oocytes.
Coello A; Pellicer A; Cobo A
Minerva Ginecol; 2018 Aug; 70(4):415-423. PubMed ID: 29527869
[TBL] [Abstract][Full Text] [Related]
50. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
[TBL] [Abstract][Full Text] [Related]
51. Fertility preservation in breast cancer with case-based examples for guidance.
Hampe ME; Rhoton-Vlasak AS
J Assist Reprod Genet; 2020 Mar; 37(3):717-729. PubMed ID: 32008180
[TBL] [Abstract][Full Text] [Related]
52. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
Danis RB; Pereira N; Elias RT
Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
[TBL] [Abstract][Full Text] [Related]
53. Influence of breast cancer prognostic factors on oocyte in vitro maturation outcomes performed for urgent fertility preservation.
Raad J; Sonigo C; Benoit A; Cedrin-Durnerin I; Sifer C; Sermondade N; Grynberg M
Hum Reprod; 2022 Jun; 37(7):1480-1488. PubMed ID: 35586947
[TBL] [Abstract][Full Text] [Related]
54. Priming Before In Vitro Maturation Cycles in Cancer Patients Undergoing Urgent Fertility Preservation: a Randomized Controlled Study.
Sonigo C; Le Conte G; Boubaya M; Ohanyan H; Pressé M; El Hachem H; Cedrin-Durnerin I; Benoit A; Sifer C; Sermondade N; Grynberg M
Reprod Sci; 2020 Dec; 27(12):2247-2256. PubMed ID: 32617881
[TBL] [Abstract][Full Text] [Related]
55. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.
Blumenfeld Z; Evron A
Expert Opin Pharmacother; 2015 May; 16(7):1009-20. PubMed ID: 25826240
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of Fertility Preservation for Female Cancer Patients in a Single Tertiary Center.
Kim JH; Alzahrani HS; Lee SR; Kim SH; Chae HD
Yonsei Med J; 2023 Aug; 64(8):497-504. PubMed ID: 37488701
[TBL] [Abstract][Full Text] [Related]
57. Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women with Malignancy.
Cohen Y; Tannus S; Volodarsky-Perel A; Son WY; Tulandi T; Buckett W
Reprod Sci; 2020 Dec; 27(12):2257-2264. PubMed ID: 32617879
[TBL] [Abstract][Full Text] [Related]
58. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes.
Segers I; Bardhi E; Mateizel I; Van Moer E; Schots R; Verheyen G; Tournaye H; De Vos M
Hum Reprod; 2020 Sep; 35(9):2026-2036. PubMed ID: 32829388
[TBL] [Abstract][Full Text] [Related]
59. Little information about fertility preservation is provided for cancer patients: A survey of oncologists' knowledge, attitude and current practice.
Vesali S; Navid B; Mohammadi M; Karimi E; Omani-Samani R
Eur J Cancer Care (Engl); 2019 Jan; 28(1):e12947. PubMed ID: 30421553
[TBL] [Abstract][Full Text] [Related]
60. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval.
Doyle JO; Richter KS; Lim J; Stillman RJ; Graham JR; Tucker MJ
Fertil Steril; 2016 Feb; 105(2):459-66.e2. PubMed ID: 26604065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
